Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
51 hedge funds and large institutions have $19.3M invested in Carisma Therapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 50 → 51 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.43% less ownership
Funds ownership: 22.5% → 21.08% (-1.4%)
27% less capital invested
Capital invested by funds: $26.6M → $19.3M (-$7.3M)
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$93.6K |
| 2 |
Invesco
Atlanta,
Georgia
|
+$66.5K |
| 3 |
State Street
Boston,
Massachusetts
|
+$59.6K |
| 4 |
Two Sigma Investments
New York
|
+$36.5K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$558K |
| 2 |
BlackRock
New York
|
-$315K |
| 3 |
Morgan Stanley
New York
|
-$297K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$231K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$81.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Dimensional Fund Advisors
Austin,
Texas
| – | -$81.6K | -27,843 | Closed |
|
52
SG Americas Securities
New York
| – | -$43K | -14,671 | Closed |
|
53
VOYA Investment Management
Atlanta,
Georgia
| – | -$31.7K | -10,822 | Closed |
|
54
Goldman Sachs
New York
| – | -$30.8K | -10,519 | Closed |
|
55
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$29.5K | -10,062 | Closed |
|
|
OP
56
ORG Partners
Roanoke,
Indiana
| – | -$586 | -200 | Closed |
|
57
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$10 | +4 | New |
|
CARM Hedge Fund Activity: Q1 2024 in Review
51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2024, worth a combined $19.3M — down 27% from $26.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CARM positions and 7 closed out — a net gain of 1 holder — while 11 added to existing stakes and 19 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $93.6K. The largest seller was TPG GP A, cutting an estimated $558K.
- 51 institutional investors held Carisma Therapeutics (CARM) as of Q1 2024, up from 50 in Q4 2023.
- Funds reported $19.3M of Carisma Therapeutics stock for Q1 2024, down 27% quarter-over-quarter.
- 8 funds opened new Carisma Therapeutics positions in Q1 2024 and 7 closed out, a net change of +1 holder.
- The largest Carisma Therapeutics buyer in Q1 2024 was Citadel Advisors, an estimated $93.6K added.
- The largest Carisma Therapeutics seller in Q1 2024 was TPG GP A, an estimated $558K sold.
Based on aggregated 13F filings for Q1 2024.